Assembly Biosciences is well-positioned to capitalize on the growing market for treatments of recurrent genital herpes and hepatitis B virus with a strong pipeline and potential partnerships.
Bears say
Assembly Biosciences is currently facing risks and uncertainties with their experimental therapies, such as the potential for adverse side effects and the need for further clinical trials. Additionally, the company recently raised funds through a stock offering, which could dilute current shareholders' value. Furthermore, while the company's pipeline shows potential for various diseases, the success of these programs and any potential expansion opportunities are still uncertain.
Assembly Biosciences (ASMB) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.
This aggregate rating is based on analysts' research of Assembly Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Get the latest Assembly Biosciences (ASMB) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis
Analysts have given Assembly Biosciences (ASMB) a Buy based on their latest research and market trends.
According to 4 analysts, Assembly Biosciences (ASMB) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.
Wall Street analysts have set a price target of $44, reflecting a 0.00% increase from the current stock price.
Financial analysts have set a price target of $44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.
Get the latest Assembly Biosciences (ASMB) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.